NEW YORK (TheStreet) -- Cara Therapeutics (CARA) - Get Report stock is down by 36.02% to $4.42 on heavy trading volume on Friday, after the FDA placed a trial for the company's postoperative pain treatment on hold.
The Shelton, CT-based clinical-stage bio-pharmaceutical company announced on Thursday that the FDA placed the Phase 3 trial on hold in order to conduct a safety review.
The trial was halted after some patients exceeded a certain level of serum sodium levels, which triggered a stopping rule, Cara said in a statement on Thursday.
The initial results of the safety review show that no serious adverse events have been reported in connection with the trial, the company added.
"We look forward to continuing the study, pending FDA review, as we work to bring this novel class of therapeutics to patients in need of additional pain treatment options," CEO Derek Chalmers said in a statement.
So far today, 1.23 million shares of Cara have traded, well above the company's 30-day average of about 391,000 shares.
Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rates this stock as a "sell" with a ratings score of D. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.
You can view the full analysis from the report here: CARA